Business Wire

Flow Pharma, Inc. and OncoImmunity AS partner for the Development of FlowVaxTM Personalized Cancer Vaccines

Jaa

Flow Pharma Inc., a San Francisco Bay Area biotechnology company focused on developing personalized cancer vaccines, today announced a collaboration with Norwegian bioinformatics company OncoImmunity AS.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190312005768/en/

Under the agreement OncoImmunity will license the Immuneoprofiler™ software to Flow Pharma to support the clinical development and commercialisation of products based on the FlowVax platform. The Immuneoprofiler™ has recently received the CE-IVD mark certification as a medical device, and fills some of the key gaps in neoantigen prediction. The FlowVax vaccine platform developed by Flow Pharma, is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. OncoImmunity will develop a customised machine-learning layer, using clinical data generated by Flow Pharma, that will work-in-sync with the Immuneoprofiler™ software to make predictions tailored to the FlowVax platform.

This exciting partnership and licensing deal represents a fantastic opportunity for OncoImmunity to apply its Immuneoprofiler™ prediction software to the FlowVax technology in a clinical setting. It also affords OncoImmunity the opportunity to leverage its in-depth knowledge of immune-informatics and expertise in machine learning to develop a customised solution for the FlowVax platform that will support Flow Pharma’s needs now and in the years ahead” said Richard Stratford., Chief Executive Officer at OncoImmunity.

“We believe that OncoImmunity’s Immuneoprofiler™ software represents the best-in-class solution for predicting clinically relevant bona fide neoantigens. Flow Pharma’s bioinformatics team will be working closely with OncoImmunity AS to customize the way we utilize Immuneoprofiler™ in order to optimize the use of the data we will be generating” said Reid Rubsamen, M.D., CEO of Flow Pharma.

About OncoImmunity

OncoImmunity AS is a machine-learning company offering a proprietary technology to address key knowledge gaps in the prediction of bona fide immunogenic neoantigen for personalized cancer immunotherapy. OncoImmunity's software facilitates effective patient selection for cancer immunotherapy and identifies neoantigen targets creating truly personalized cancer vaccines & cell therapies in clinically actionable time-frames.

About Flow Pharma

Flow Pharma Inc. is a San Francisco Bay Area based, biotechnology company developing personalized neoantigen-based vaccines based on its proprietary FlowVax vaccine platform.

The FlowVax platform is optimized to simultaneously deliver multiple neoantigen peptide targets to enhance tumor-specific killer T-cell attack. Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. Flow Pharma is now gearing up to test therapeutic cancer vaccines based on the FlowVax platform.

About FlowVax TM

Each of the chemical components used in the FlowVax platform are currently part of an FDA approved vaccine or pharmaceutical, simplifying the regulatory pathway. FlowVax vaccines can also be manufactured quickly and efficiently, keeping the cost down and getting the therapy in the hands of treating physicians soon after the diagnosis is made, for maximum efficacy.

However, as with all personalized vaccine approaches, the successful development and commercialisation of products based on the FlowVax platform is predicated on being able to identify clinically actionable and immunogenic neoantigen targets in a cost effective and clinically actionable time-frame. OncoImmunity’s Immuneoprofiler™ software, addresses this challenge, by harnessing the power of artificial intelligence (AI) to identify clinically relevant and immunogenic neoantigens from next generation sequencing data.

Forward Looking Statements

This press release may contain forward-looking statements, including information about management's view of Flow Pharma, Inc. (''the Company''), future expectations, plans and prospects. In particular, when used in the preceding discussion, the words ''believes,''''expects,''''intends,''''plans,''''anticipates,'' or ''may,'' and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.

Contact information

Trevor Clancy Ph.D.
CSO OncoImmunity
E-mail: trevor@oncoimmunity.com
Phone: + 47 41 43 12 42

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Andersen Global Expands UK Locations23.5.2019 16:30:00 EESTTiedote

Claritas Tax Limited, a Birmingham, United Kingdom-based collaborating firm of Andersen Global, has opened a new office location in Deansgate, Manchester city center. This means that Andersen Global now has a presence in six locations in the UK through its member firms and collaborating firms. “Now more than ever, it’s important that businesses have easy access to quality advice in the UK’s dynamic political and business environment. The addition of another location in the region adds to our existing capabilities and will allow us to continue providing best-in-class service,” said Mark Vorsatz, Andersen Global Chairman and CEO of Andersen Tax LLC. Founded in 2012, Claritas Tax Limited has a list of clientele from entrepreneurial, privately owned, venture capital, and private equity owned businesses, listed companies and stakeholders. Claritas provides a broad range of tax consulting services, including all aspects of M&A and transactional taxes, R&D and Intellectual Property claims, sh

Mindbreeze Receives Attestation in Accordance with BSI Cloud Requirements23.5.2019 16:11:00 EESTTiedote

Mindbreeze receives attestation for its Mindbreeze InSpire SaaS service according to the specifications of the C5 catalogue of requirements (Cloud Computing Compliance Controls Catalogue, abbreviated C5), published by the German Federal Office for Information Security (BSI). The Mindbreeze InSpire SaaS service is professionally operated in Mindbreeze data centers on behalf of the customers. The attestation was issued by KPMG Alpen-Treuhand GmbH Wirtschaftsprüfungs- und Steuerberatungsgesellschaft. “The number of cloud services in the field of data analysis is growing steadily. This makes it all the more essential for customers to take a closer look at the choice of suppliers. C5 provides the regulatorily defined IT security level, which is comparable to the IT basic protection level that is increased by cloud controls,” explains Klaus Schatz, Managing Director of KPMG Advisory GmbH. C5 attestation (ISAE 3000 Report Type 2) is a recognized and authoritative verification for all customer

Bacardi Limited Announces 5th Annual Good Spirited Awards for Employee-Led Global Environmental Sustainability Programs23.5.2019 15:15:00 EESTTiedote

In continuation of its ongoing sustainability efforts, Bacardi Limited is proud to announce the recipients of its 5th annual Bacardi Limited Good Spirited Awards. Launched in 2014, the awards recognize the employees, teams and facilities across the company’s global network that developed the best environmental programs across five different categories: Production Facility, Brand Innovation, Sustainable Office, Green Champions or Partnerships. This year’s winners instituted programs to shift to renewable energy, reduce water use and waste, increase recycling efforts and amplify the Bacardi Limited No Straws campaign to decrease the amount of single-use plastic straws by one billion over the next two years. The awards acknowledge activities that took place between April 1, 2018 and March 31, 2019. “Bacardi Limited’s Good Spirited Awards truly underscore the company’s foundation and support of global environmental sustainability efforts at our facilities and in our communities,” says Rick

Teridion Announces Deep Integration with Cisco Meraki MX Security and SD-WAN Appliances to Deliver New High Performance Internet Service23.5.2019 15:00:00 EESTTiedote

Teridion, the company delivering the only global public cloud-based WAN service, today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service. For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications

C.H. Robinson Acquires Dema Service S.p.A. to Expand Global Presence23.5.2019 14:00:00 EESTTiedote

C.H. Robinson (NASDAQ: CHRW) continues to expand its global footprint with its announcement of the acquisition of Dema Service S.p.A. (Dema Service) on May 22, 2019. Dema Service is a leading provider of European road transportation based in Italy. “The acquisition of Dema Service is an exciting milestone for C.H. Robinson and will strengthen our existing footprint in Italy, one of the largest road transportation markets in Europe,” said Jeroen Eijsink, President of Europe for C.H. Robinson. “We are eager to work with Dema Service’s customers to offer our full suite of logistics services to help improve their supply chains.” This is the second European acquisition for C.H. Robinson in 2019. The company recently acquired the freight forwarding group Space Cargo, which expanded C.H. Robinson’s presence in Spain and Columbia. Dema Service is a privately-owned logistics company providing road transportation services across Europe. Headquartered in Pescara, Italy, Dema Service has approxima

Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform23.5.2019 13:30:00 EESTTiedote

Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/ FFPE IF of tonsil, 6-plex + DAPI. Total staining time: 4h12 (with Opal® 7-Color Manual IHC Kit) (Photo: Business Wire) Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market. LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manua

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme